Q3 FY2026 · ended Sep 30, 2026 · Revenue $12.67M, +1325.1% YoY · Filed Nov 2, 2026
Crispr Therapeutics AG (CRSP) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $12.7 million and a net loss of $111.4 million. Free cash flow was -$90.1 million. As of Sep 30, 2026 it held $2.3 billion in cash and investments and $779.8 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CRSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zug
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1674416
- Former names
- CRISPR Therapeutics AG (until Nov 2, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $12.7M | $10.2M | $1.5M | $864,000 | $889,000 |
| Operating income | -$130.0M | -$117.3M | -$130.2M | -$154.8M | -$132.1M |
| Net income | -$111.4M | -$91.2M | -$122.9M | -$130.6M | -$106.4M |
| Diluted EPS | -$1.15 | -$0.94 | -$1.28 | -$1.37 | -$1.17 |
| Operating cash flow | -$89.7M | -$83.5M | -$108.9M | -$92.6M | -$84.6M |
| Free cash flow | -$90.1M | -$84.1M | -$109.4M | -$93.1M | -$84.7M |
| Total assets | $2.6B | $2.7B | $2.7B | $2.3B | $2.2B |
| Total liabilities | $908.3M | $904.2M | $911.3M | $343.4M | $329.3M |
| Stockholders' equity | $1.6B | $1.7B | $1.8B | $1.9B | $1.9B |
| Cash and investments | $2.3B | $2.4B | $2.4B | $2.0B | $1.9B |
| Total debt | $779.8M | $783.7M | $787.6M | $206.7M | $211.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 2, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 19, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
All 880 Crispr Therapeutics AG SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.